AUSTIN, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. VRML, a bioanalytical-based women's health company focused on gynecologic disease, today announced that it will report financial results for the three and six months ended June 30, 2019 on Thursday, August 8, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Thursday, August 8th @ 4:30pm Eastern Time | |
Domestic: International: Conference ID: Webcast: | 855-327-6837 631-891-4304 10007441 http://public.viavid.com/index.php?id=135718 |
About Vermillion, Inc.
Vermillion, Inc. is dedicated to the discovery; development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use.
Visit www.vermillion.com or more information.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
Arr@LifeSciAdvisors.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.